UM Ventures, Baltimore Launchpad
A $2M SBIR Grant is Supporting Isoprene's Advancement
The early-stage small molecule oncology company is developing therapeutics for triple negative breast cancer and other cancers.
Advancing UMB Startups
UM Ventures, Baltimore Launchpad works with faculty inventors to spin out startup companies around highly-promising UMB intellectual property. In this unique initiative, our experienced business development team – all of whom are employed by UMB – take management roles within the company and work alongside the inventors, helping them de-risk and advance the technology and company.
Living Pharma was acquired by Lentigen Techology, a Miltenyi Biotec Company, in 2017, just two years after it was established. The immunotherapy company was developing a universal CAR-T cell therapy.
Isoprene Pharmaceuticals was launched in 2018 and is developing small molecules for oncology and dermatology applications. In 2020, the company received investment from and entered into an exclusive licensing agreement with a strategic partner. In 2021, they were awarded a $2 million Phase II SBIR grant from the National Cancer Institute.
SurgiGYN was launched in 2016 to develop minimally invasive surgical devices for gynecological surgery. The company received two investments from a strategic partner before being acquired by that partner in early 2020.